应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00512 远大医药
休市中 08-16 16:08:20
4.610
+0.060
+1.32%
最高
4.630
最低
4.540
成交量
260.85万
今开
4.630
昨收
4.550
日振幅
1.98%
总市值
163.64亿
流通市值
163.64亿
总股本
35.50亿
成交额
1,199万
换手率
0.07%
流通股本
35.50亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
远大医药:中期净利润预增超 50% 4.66 港元
和讯网 · 08-15 10:15
远大医药:中期净利润预增超 50% 4.66 港元
远大医药高开逾3% 预期上半年股东应占综合净利润增超50%
新浪港股 · 08-15 09:37
远大医药高开逾3% 预期上半年股东应占综合净利润增超50%
港股异动 | 远大医药(00512)盈喜后高开逾3% 预期上半年股东应占综合净利润增超50%
智通财经网 · 08-15 09:22
港股异动 | 远大医药(00512)盈喜后高开逾3% 预期上半年股东应占综合净利润增超50%
远大医药:预计2024年6月30日截止的综合净利润将比2023年同期增长不低于50%
金融界港股 · 08-14 17:52
远大医药:预计2024年6月30日截止的综合净利润将比2023年同期增长不低于50%
《盈喜》远大医药(00512.HK)料中期净利润按年增最少50%
阿斯达克财经 · 08-14 17:38
《盈喜》远大医药(00512.HK)料中期净利润按年增最少50%
远大医药(00512)发盈喜,预期上半年股东应占综合净利润取得不低于50%的增长
智通财经 · 08-14 17:36
远大医药(00512)发盈喜,预期上半年股东应占综合净利润取得不低于50%的增长
远大医药(00512.HK)将于8月19日举行董事会会议以审批中期业绩
格隆汇资讯 · 08-08
远大医药(00512.HK)将于8月19日举行董事会会议以审批中期业绩
翼状胬肉重磅单品CBT-001海外权益落地,远大医药(00512)前瞻布局凸显战略眼光
智通财经 · 08-07
翼状胬肉重磅单品CBT-001海外权益落地,远大医药(00512)前瞻布局凸显战略眼光
港股概念追踪 |四川将形成世界级核医疗产业发展高地 核药高壁垒造就寡头垄断格局(附概念股)
智通财经 · 08-06
港股概念追踪 |四川将形成世界级核医疗产业发展高地 核药高壁垒造就寡头垄断格局(附概念股)
远大医药(00512)出现大手卖出110万股,成交价$4.46,涉资490.6万
阿斯达克财经 · 07-31
远大医药(00512)出现大手卖出110万股,成交价$4.46,涉资490.6万
平安证券:核药具有多重临床优势 高壁垒造就寡头垄断格局
智通财经 · 07-18
平安证券:核药具有多重临床优势 高壁垒造就寡头垄断格局
【中金:首予远大医药(00512.HK)“跑赢行业”评级 目标价5.4港元】智通财经APP获悉,中金发布研究报告称,首予远大医药(00512.
智通财经 · 07-18
【中金:首予远大医药(00512.HK)“跑赢行业”评级 目标价5.4港元】智通财经APP获悉,中金发布研究报告称,首予远大医药(00512.
中金:首予远大医药(00512)“跑赢行业”评级 目标价5.4港元
智通财经 · 07-18
中金:首予远大医药(00512)“跑赢行业”评级 目标价5.4港元
智通港股早知道 | 两部门再出减税惠企大礼包 华为Pura 70系列手机爆火
智通财经 · 07-18
智通港股早知道 | 两部门再出减税惠企大礼包 华为Pura 70系列手机爆火
远大医药完成对天津田边和百济制药的收购
新京报 · 07-17
远大医药完成对天津田边和百济制药的收购
优势领域同步发力,远大医药(00512)完成收购天津田边及百济制药,加码慢性疾病及过敏性鼻炎两大赛道
智通财经网 · 07-17
优势领域同步发力,远大医药(00512)完成收购天津田边及百济制药,加码慢性疾病及过敏性鼻炎两大赛道
远大医药(00512)完成对天津田边和百济制药的收购
智通财经 · 07-17
远大医药(00512)完成对天津田边和百济制药的收购
【远大医药(00512.HK)完成对天津田边和百济制药的收购】智通财经APP讯,远大医药(00512.HK)发布公告,集团近日分别完成了对天津田边制药有限公司(天津田边)以及南昌百济制药有限公司和江西百安百煜医药科技有限公司(以下两者合称“百济制药”)100%股权的变更登记,这两项收购将会进一步深化集团在心脑血管急救板块和呼吸及危重症板块的产业布局。
智通财经 · 07-17
【远大医药(00512.HK)完成对天津田边和百济制药的收购】智通财经APP讯,远大医药(00512.HK)发布公告,集团近日分别完成了对天津田边制药有限公司(天津田边)以及南昌百济制药有限公司和江西百安百煜医药科技有限公司(以下两者合称“百济制药”)100%股权的变更登记,这两项收购将会进一步深化集团在心脑血管急救板块和呼吸及危重症板块的产业布局。
远大医药(00512.HK)完成收购两间医药相关公司
阿斯达克财经 · 07-17
远大医药(00512.HK)完成收购两间医药相关公司
南向资金7月10日净买入远大医药57.30万股 连续5日增持
自选股智能写手 · 07-11
南向资金7月10日净买入远大医药57.30万股 连续5日增持
公司概况
公司名称:
远大医药
所属市场:
SEHK
上市日期:
--
主营业务:
远大医药健康控股有限公司是一家主要从事制造及销售医药制剂及医疗器械的香港投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械、生物技术产品及营养产品、精品原料药和其他产品。该公司的主要产品涵盖抗肿瘤、心血管急救制剂及高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科以及生物健康产品和精品原料药。
发行价格:
--
{"stockData":{"symbol":"00512","market":"HK","secType":"STK","nameCN":"远大医药","latestPrice":4.61,"timestamp":1723795700011,"preClose":4.55,"halted":0,"volume":2608500,"delay":0,"floatShares":3549571148,"shares":3549571148,"eps":0.535954,"marketStatus":"休市中","marketStatusCode":7,"change":0.06,"latestTime":"08-16 16:08:20","open":4.63,"high":4.63,"low":4.54,"amount":11986883,"amplitude":0.01978,"askPrice":4.61,"askSize":9000,"bidPrice":4.6,"bidSize":500,"shortable":3,"etf":0,"ttmEps":0.535954,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724031000000},"adr":0,"listingDate":819302400000,"adjPreClose":4.55,"dividendRate":0.056399,"openAndCloseTimeList":[[1723771800000,1723780800000],[1723784400000,1723795200000]],"volumeRatio":2.032333,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00512/wiki","defaultTab":"wiki","newsList":[{"id":"2459692404","title":"远大医药:中期净利润预增超 50% 4.66 港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2459692404","media":"和讯网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459692404?lang=zh_cn&edition=full","pubTime":"2024-08-15 10:15","pubTimestamp":1723688145,"startTime":"0","endTime":"0","summary":"【远大医药发盈喜,股价高开上涨 3.33%】远大医药发布公告,预期截至 2024 年 6 月 30 日止期间,公司拥有人应占综合净利润与 2023 年同期相比将增长不低于 50%。2023 年 6 月 30 日止期间,公司拥有人应占未经审核综合净利润约为 10.29 亿港元。目前,其股价为 4.66 港元,成交额 38.91 万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408151038289f2c3719&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408151038289f2c3719&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00512"],"gpt_icon":0},{"id":"2459450441","title":"远大医药高开逾3% 预期上半年股东应占综合净利润增超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459450441","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459450441?lang=zh_cn&edition=full","pubTime":"2024-08-15 09:37","pubTimestamp":1723685823,"startTime":"0","endTime":"0","summary":"远大医药(00512)发盈喜后高开,股价上涨3.33%,报4.66港元,成交额38.91万港元。\n 远大医药(00512)发布公告,预期截至2024年6月30日止期间的公司拥有人应占综合净利润与截至2023年6月30日止期间比较将取得不低于50%的增长(截至2023年6月30日止期间的公司拥有人应占未经审核综合净利润约为10.29亿港元)。该\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-15/doc-incisrnm8621027.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-15/doc-incisrnm8621027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["00512"],"gpt_icon":0},{"id":"2459457949","title":"港股异动 | 远大医药(00512)盈喜后高开逾3% 预期上半年股东应占综合净利润增超50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459457949","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459457949?lang=zh_cn&edition=full","pubTime":"2024-08-15 09:22","pubTimestamp":1723684970,"startTime":"0","endTime":"0","summary":"远大医药(00512)盈喜后高开逾3%,截至发稿,涨3.33%,报4.66港元,成交额38.91万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/source/image/47101.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/source/image/47101.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1164355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00512"],"gpt_icon":0},{"id":"2459121814","title":"远大医药:预计2024年6月30日截止的综合净利润将比2023年同期增长不低于50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459121814","media":"金融界港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459121814?lang=zh_cn&edition=full","pubTime":"2024-08-14 17:52","pubTimestamp":1723629145,"startTime":"0","endTime":"0","summary":"金融界8月14日消息,远大医药发布业绩预告,根据尚未经审核的管理账目预计,2024年6月30日止的综合净利润将比2023年同期增长不低于50%(2023年6月30日止的未经审核的综合净利润为港币1,029,354,000)。这一增长主要得益于公司在海外企业Telix Pharmaceuticals Limited的股票投资因应市场变动录得的公允价值变动收益增加了约港币247,480,000,以及2023年的一次性支出港币323,390,000在2024年已无。以上数据未经审核。\n\n\r\n 责任编辑:十八","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/14175242353758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["00512"],"gpt_icon":0},{"id":"2459140173","title":"《盈喜》远大医药(00512.HK)料中期净利润按年增最少50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459140173","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459140173?lang=zh_cn&edition=full","pubTime":"2024-08-14 17:38","pubTimestamp":1723628280,"startTime":"0","endTime":"0","summary":"远大医药发布业绩预告,预期截至2024年6月30止中期综合净利润将按年增长不低于50%,而2023年同期综合净利润约10.29亿元,主要来自于期内在海外企业Telix Pharmaceuticals Limited的股票投资录得公允价值变动收益增加,以及去年同期因一次性支出录得其他亏损,而今年上半年再无此支出而录得净其他收益所致。(港股报价延迟最少十五分钟。沽空资料截至 2024-08-14 16:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240508115941767_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240508115941767_s.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1371597/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00512"],"gpt_icon":0},{"id":"2459147414","title":"远大医药(00512)发盈喜,预期上半年股东应占综合净利润取得不低于50%的增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2459147414","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459147414?lang=zh_cn&edition=full","pubTime":"2024-08-14 17:36","pubTimestamp":1723628218,"startTime":"0","endTime":"0","summary":"智通财经APP讯,远大医药(00512)发布公告,预期截至2024年6月30日止期间的公司拥有人应占综合净利润与截至2023年6月30日止期间比较将取得不低于50%的增长(截至2023年6月30日止期间的公司拥有人应占未经审核综合净利润约为10.29亿港元)。该增长的主要原因(除其他因素外)为:集团于海外企业Telix Pharmaceuticals Limited的股票投资因应市场变动取得公允价值变动收益约4.766亿港元较去年同期增加了约2.47亿港元;及2023年因一次性支出约3.23亿港元而取得的其他亏损,2024年再无此支出而取得净其他收益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1164055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512"],"gpt_icon":0},{"id":"2457396007","title":"远大医药(00512.HK)将于8月19日举行董事会会议以审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2457396007","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457396007?lang=zh_cn&edition=full","pubTime":"2024-08-08 18:25","pubTimestamp":1723112758,"startTime":"0","endTime":"0","summary":"格隆汇8月8日丨远大医药(00512.HK)发布公告,公司将于2024年8月19日举行董事会会议,藉以(其中包括)考虑及批准公司及其附属公司截至2024年6月30日止6个月的中期业绩以及其他事项(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408081826079f1a39c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408081826079f1a39c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0},{"id":"2457895648","title":"翼状胬肉重磅单品CBT-001海外权益落地,远大医药(00512)前瞻布局凸显战略眼光","url":"https://stock-news.laohu8.com/highlight/detail?id=2457895648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457895648?lang=zh_cn&edition=full","pubTime":"2024-08-07 16:03","pubTimestamp":1723017834,"startTime":"0","endTime":"0","summary":"填补翼状胬肉治疗市场空白,CBT-001有望重塑治疗标准翼状胬肉为一种眼表良性增生性疾病,主要特征是生长在角膜边缘上呈翼状纤维血管的结膜组织。中国治疗翼状胬肉药物的市场规模预计于2027年达到2.18亿美元,于2032年达到20.22亿美元,复合年增长率为56.1%。全球范围内仅有3款适用于预防翼状胬肉生长及减少结膜充血的临床阶段候选药物,其中两款处于II期临床试验阶段,CBT-001是唯一处于三期临床试验阶段的药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1161026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00512","CBT","BK4090"],"gpt_icon":0},{"id":"2457306838","title":"港股概念追踪 |四川将形成世界级核医疗产业发展高地 核药高壁垒造就寡头垄断格局(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2457306838","media":"智通财经","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457306838?lang=zh_cn&edition=full","pubTime":"2024-08-06 12:34","pubTimestamp":1722918864,"startTime":"0","endTime":"0","summary":"到2030年建成全球最大的医用同位素生产基地、全国最大的放射性药物和核医疗装备生产聚集地、全国最好的核医疗中心,形成世界级核医疗产业发展高地。这是诺华在中国的首个放射配体疗法生产基地,也是在中国的第二个创新药物生产基地,投资总额预计6亿元。平安证券发布研究报告称,截止2024年7月4日,全球有88款放射性新药获批上市,仅有18款用于治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1160414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159891","HSTECH","HSCEI","01763","00512","BK1191","YANG","BK1222"],"gpt_icon":1},{"id":"2455033789","title":"远大医药(00512)出现大手卖出110万股,成交价$4.46,涉资490.6万","url":"https://stock-news.laohu8.com/highlight/detail?id=2455033789","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455033789?lang=zh_cn&edition=full","pubTime":"2024-07-31 16:08","pubTimestamp":1722413280,"startTime":"0","endTime":"0","summary":"[大手成交]远大医药(00512)在下午04:08出现大手卖出,成交量为110万,成交价为港币$4.46,涉资490.6万。至目前为止,股价升2.294%,今日最高价为$4.5,而最低价为$4.32,总成交量为348.046万股,总成交金额港币$1.544千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2407317097/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00512","BK1191"],"gpt_icon":0},{"id":"2452485935","title":"平安证券:核药具有多重临床优势 高壁垒造就寡头垄断格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2452485935","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452485935?lang=zh_cn&edition=full","pubTime":"2024-07-18 20:31","pubTimestamp":1721305897,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,平安证券发布研究报告称,截止2024年7月4日,全球有88款放射性新药获批上市,仅有18款用于治疗。平安证券观点如下:核药应用于临床诊断和治疗,具有多重优势:放射性核素指原子核不稳定,在衰变成其他核素时会自发性地放出电离辐射的核素, 用其制成的特殊制剂为放射性药物,也称核药。1)核素生产阶段:反应堆辐照为放射性核素主要生产方式,具有极高资金、建设和审批壁垒,因此上游核素供应商对下游有强话语权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152868.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1222","LU0196878994.USD","161027","01763","06990","00512","BK1161"],"gpt_icon":0},{"id":"2452145766","title":"【中金:首予远大医药(00512.HK)“跑赢行业”评级 目标价5.4港元】智通财经APP获悉,中金发布研究报告称,首予远大医药(00512.","url":"https://stock-news.laohu8.com/highlight/detail?id=2452145766","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452145766?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:30","pubTimestamp":1721266235,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["159992","BK1574","06978","00512","BK1191","BK1161"],"gpt_icon":0},{"id":"2452145717","title":"中金:首予远大医药(00512)“跑赢行业”评级 目标价5.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452145717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452145717?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:30","pubTimestamp":1721266235,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,中金发布研究报告称,首予远大医药“跑赢行业”评级,预计2024-2025年EPS分别为0.57港币、0.60港币,CAGR为6.7%,目标价5.4港元。2023年公司继续坚持股东回报,公告拟派息每股0.26港币,派息率达47.7%。公司实现易甘泰钇[90Y]微球注射液国内商业化,2023销售额达2.17亿港币,同比增长261%。2023年12月,公司开启对重庆多普泰及天津田边的收购进程,该行认为公司正通过内生+外延扩展其传统领域协同,有望进入更多元化增长阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00512"],"gpt_icon":0},{"id":"2452111266","title":"智通港股早知道 | 两部门再出减税惠企大礼包 华为Pura 70系列手机爆火","url":"https://stock-news.laohu8.com/highlight/detail?id=2452111266","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452111266?lang=zh_cn&edition=full","pubTime":"2024-07-18 07:40","pubTimestamp":1721259616,"startTime":"0","endTime":"0","summary":"华为Pura 70系列手机爆火!出货量比P60系列增长125%7月17日,中国证券报·中证金牛座记者从华为内部人士获悉,自4月18日Pura70系列开启先锋计划销售以来,截至7月16日,华为Pura 70系列出货量比同期P60系列增长125%。增持后最新持股数目约为15.38亿股,持股比例为61.69%。华润博雅生物以自有资金18.2亿元收购GC集团持有的绿十字香港控股有限公司100%股权,从而间接收购境内血液制品主体绿十字(中国)生物制品有限公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1522","BK1116","01788","BK1546","BK1565","HSCEI","BK1225","03898","IE0032431581.USD","HSTECH","BK1515","01072","BK1171","01053","00512","BK1594","BK1205","BK1147","BK1161","BK1568","BK1583","YANG","01877","BK1191","07226"],"gpt_icon":0},{"id":"2452415750","title":"远大医药完成对天津田边和百济制药的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2452415750","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452415750?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:36","pubTimestamp":1721223379,"startTime":"0","endTime":"0","summary":"新京报讯(记者王卡拉)7月17日,远大医药发布公告,公司近日分别完成对天津田边制药(简称“天津田边”)、南昌百济制药有限公司和江西百安百亿医药科技有限公司(两者合称“百济制药”)100%股权的变更登记,两项收购将会进一步深化其在心脑血管急救板块和呼吸及危重症板块的产业布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407173133554195.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407173133554195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1191","00512","01477"],"gpt_icon":0},{"id":"2452362171","title":"优势领域同步发力,远大医药(00512)完成收购天津田边及百济制药,加码慢性疾病及过敏性鼻炎两大赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2452362171","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452362171?lang=zh_cn&edition=full","pubTime":"2024-07-17 17:58","pubTimestamp":1721210294,"startTime":"0","endTime":"0","summary":"公司对天津田边制药有限公司,以及南昌百济制药有限公司和江西百安百煜医药科技有限公司(两者合称:百济制药)100%股权的变更登记已顺利完成...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20240717/20240717175857_58564.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240717/20240717175857_58564.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152127.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["01477","BK1574","BK1191","00512"],"gpt_icon":0},{"id":"2452136399","title":"远大医药(00512)完成对天津田边和百济制药的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2452136399","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452136399?lang=zh_cn&edition=full","pubTime":"2024-07-17 17:47","pubTimestamp":1721209651,"startTime":"0","endTime":"0","summary":"智通财经APP讯,远大医药 发布公告,集团近日分别完成了对天津田边制药有限公司以及南昌百济制药有限公司和江西百安百煜医药科技有限公司100%股权的变更登记,这两项收购将会进一步深化集团在心脑血管急救板块和呼吸及危重症板块的产业布局。兹提述公司日期为2023年12月21日内容有关集团拟收购天津田边控股股权。集团附属公司北京远大九和药业有限公司近日以约2.6亿元人民币收购了百济制药100%的股权并获得其技术领先的鼻喷制剂平台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","00512","BK1191"],"gpt_icon":0},{"id":"2452136360","title":"【远大医药(00512.HK)完成对天津田边和百济制药的收购】智通财经APP讯,远大医药(00512.HK)发布公告,集团近日分别完成了对天津田边制药有限公司(天津田边)以及南昌百济制药有限公司和江西百安百煜医药科技有限公司(以下两者合称“百济制药”)100%股权的变更登记,这两项收购将会进一步深化集团在心脑血管急救板块和呼吸及危重症板块的产业布局。","url":"https://stock-news.laohu8.com/highlight/detail?id=2452136360","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452136360?lang=zh_cn&edition=full","pubTime":"2024-07-17 17:47","pubTimestamp":1721209651,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","159938","BK1191","09939","BK1161","00512","01477","BK1574"],"gpt_icon":0},{"id":"2452613546","title":"远大医药(00512.HK)完成收购两间医药相关公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2452613546","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452613546?lang=zh_cn&edition=full","pubTime":"2024-07-17 17:34","pubTimestamp":1721208840,"startTime":"0","endTime":"0","summary":"远大医药公布,于近日分别完成对天津田边制药有限公司,以及南昌百济制药有限公司和江西百安百煜医药科技有限公司100%股权的变更登记。公司表示,上述两项收购将会进一步深化集团在心脑血管急救板块和呼吸及危重症板块的产业布局。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20240508115940532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20240508115940532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1364370/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1191","BK1574","159938","09939","BK1161","00512"],"gpt_icon":0},{"id":"2450587141","title":"南向资金7月10日净买入远大医药57.30万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2450587141","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450587141?lang=zh_cn&edition=full","pubTime":"2024-07-11 09:31","pubTimestamp":1720661490,"startTime":"0","endTime":"0","summary":"7月10日, 南向资金增持远大医药57.30万股,连续5日增持。截止当日收盘,港股通共持有远大医药33391.31万股,占流通股9.40%。港股通增持金额前五个股分别为中国移动、建设银行、中远海控、农夫山泉、工商银行。远大医药近5个交易日下跌1.88%,港股通累计增持220.40万股;近20个交易日下跌2.70%,港股通累计增持641.05万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407110942279f3114f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407110942279f3114f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00512"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chinagrandpharm.com","stockEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":0.0066},{"period":"3month","weight":-0.0996},{"period":"6month","weight":0.3023},{"period":"1year","weight":0.0796},{"period":"ytd","weight":0.1271}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":-0.0174},{"period":"3month","weight":-0.1086},{"period":"6month","weight":0.0667},{"period":"1year","weight":-0.0489},{"period":"ytd","weight":0.0225}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"远大医药健康控股有限公司是一家主要从事制造及销售医药制剂及医疗器械的香港投资控股公司。该公司主要从事制造及销售医药制剂及医疗器械、生物技术产品及营养产品、精品原料药和其他产品。该公司的主要产品涵盖抗肿瘤、心血管急救制剂及高端心脑血管介入医疗器械、抗病毒抗感染、呼吸及五官科以及生物健康产品和精品原料药。","yearOnYearQuotes":[{"month":1,"riseRate":0.482759,"avgChangeRate":0.094346},{"month":2,"riseRate":0.689655,"avgChangeRate":0.105408},{"month":3,"riseRate":0.37931,"avgChangeRate":0.012932},{"month":4,"riseRate":0.62069,"avgChangeRate":0.018409},{"month":5,"riseRate":0.448276,"avgChangeRate":0.071029},{"month":6,"riseRate":0.344828,"avgChangeRate":-0.050119},{"month":7,"riseRate":0.37931,"avgChangeRate":-0.015206},{"month":8,"riseRate":0.413793,"avgChangeRate":0.005426},{"month":9,"riseRate":0.464286,"avgChangeRate":-0.045547},{"month":10,"riseRate":0.535714,"avgChangeRate":-0.01036},{"month":11,"riseRate":0.535714,"avgChangeRate":0.091557},{"month":12,"riseRate":0.5,"avgChangeRate":-0.008312}],"exchange":"SEHK","name":"远大医药","nameEN":"GRAND PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"远大医药,00512,远大医药股票,远大医药股票老虎,远大医药股票老虎国际,远大医药行情,远大医药股票行情,远大医药股价,远大医药股市,远大医药股票价格,远大医药股票交易,远大医药股票购买,远大医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"远大医药(00512)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供远大医药(00512)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}